Research Progress of Circulating Tumor DNA in Diagnosis and Treatment of Ovarian Cancer

doi:10.12280/gjfckx.20210694

Abstract

Abstract:

Ovarian cancer (OC) has become one of the major diseases threatening women′s life and health due to its high recurrence rate and mortality with its incidence rate increasing. At present, there is a lack of effective methods for early detection, screening, recurrence monitoring and treatment evaluation of OC. Circulating tumor DNA (ctDNA) is fragment of DNA released by tumor cells into the blood circulation. It has the advantages of noninvasive, real-time, and can reflect the characteristics of tumor genes. Recent years, with the advancement of ctDNA detection technology and the in-depth research of ctDNA, ctDNA has shown more advantages than traditional histological, serological and imaging detection methods in the early diagnosis, tumor molecular typing and treatment monitoring of OC. This paper will review the extraction and detection methods of ctDNA and its latest research progress in the diagnosis and treatment of OC, to provide new ideas for the diagnosis and treatment of OC.

Key words: DNA,neoplasm, Ovarian neoplasm, Diagnosis, Therapy, Prognosis

YU Chang-qing, WANG Xi-peng. Research Progress of Circulating Tumor DNA in Diagnosis and Treatment of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(1): 19-23.

References 34

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660. doi: 10.3322/caac.21660
[2]	Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4):284-296. doi: 10.3322/caac.21456. doi: 10.3322/caac.21456
[3]	Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients[J]. Oncology, 1989, 46(5):318-322. doi: 10.1159/000226740. doi: 10.1159/000226740 pmid: 2779946
[4]	Corcoran RB, Chabner BA. Application of Cell-free DNA Analysis to Cancer Treatment[J]. N Engl J Med, 2018, 379(18):1754-1765. doi: 10.1056/NEJMra1706174. doi: 10.1056/NEJMra1706174
[5]	Shi J, Zhang R, Li J, et al. Size profile of cell-free DNA: A beacon guiding the practice and innovation of clinical testing[J]. Theranostics, 2020, 10(11):4737-4748. doi: 10.7150/thno.42565. doi: 10.7150/thno.42565
[6]	Fong SL, Zhang JT, Lim CK, et al. Comparison of 7 methods for extracting cell-free DNA from serum samples of colorectal cancer patients[J]. Clin Chem, 2009, 55(3):587-589. doi: 10.1373/clinchem.2008.110122. doi: 10.1373/clinchem.2008.110122
[7]	Khakoo S, Georgiou A, Gerlinger M, et al. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer[J]. Crit Rev Oncol Hematol, 2018, 122:72-82. doi: 10.1016/j.critrevonc.2017.12.002. doi: 10.1016/j.critrevonc.2017.12.002
[8]	Arildsen NS, Martin de la Fuente L, Måsbäck A, et al. Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method[J]. Sci Rep, 2019, 9(1):15506. doi: 10.1038/s41598-019-51697-6. doi: 10.1038/s41598-019-51697-6
[9]	Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing[J]. Proc Natl Acad Sci U S A, 2011, 108(23):9530-9535. doi: 10.1073/pnas.1105422108. doi: 10.1073/pnas.1105422108
[10]	Gillis S, Roth A. PyClone-VI: scalable inference of clonal population structures using whole genome data[J]. BMC Bioinformatics, 2020, 21(1):571. doi: 10.1186/s12859-020-03919-2. doi: 10.1186/s12859-020-03919-2
[11]	Kalsi J, Gentry-Maharaj A, Ryan A, et al. Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)[J]. Cancers (Basel), 2021, 13(4):858. doi: 10.3390/cancers13040858. doi: 10.3390/cancers13040858
[12]	Whitwell HJ, Worthington J, Blyuss O, et al. Improved early detection of ovarian cancer using longitudinal multimarker models[J]. Br J Cancer, 2020, 122(6):847-856. doi: 10.1038/s41416-019-0718-9. doi: 10.1038/s41416-019-0718-9
[13]	Kamat AA, Sood AK, Dang D, et al. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR[J]. Ann N Y Acad Sci, 2006, 1075:230-234. doi: 10.1196/annals.1368.031. doi: 10.1196/annals.1368.031
[14]	Cohen PA, Flowers N, Tong S, et al. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening[J]. BMC Med, 2016, 14(1):126. doi: 10.1186/s12916-016-0667-6. doi: 10.1186/s12916-016-0667-6 pmid: 27558279
[15]	Wang Y, Li L, Douville C, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers[J]. Sci Transl Med, 2018, 10(433):eaap8793. doi: 10.1126/scitranslmed.aap8793. doi: 10.1126/scitranslmed.aap8793
[16]	Vanderstichele A, Busschaert P, Smeets D, et al. Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses[J]. Clin Cancer Res, 2017, 23(9):2223-2231. doi: 10.1158/1078-0432.CCR-16-1078. doi: 10.1158/1078-0432.CCR-16-1078 pmid: 27852697
[17]	Widschwendter M, Zikan M, Wahl B, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer[J]. Genome Med, 2017, 9(1):116. doi: 10.1186/s13073-017-0500-7. doi: 10.1186/s13073-017-0500-7 pmid: 29268796
[18]	Li B, Pu K, Ge L, et al. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis[J]. Gene, 2019, 714:143993. doi: 10.1016/j.gene.2019.143993. doi: 10.1016/j.gene.2019.143993
[19]	Zhang R, Pu W, Zhang S, et al. Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial[J]. PLoS One, 2018, 13(2):e0191756. doi: 10.1371/journal.pone.0191756. doi: 10.1371/journal.pone.0191756
[20]	Dvorská D, Braný D, Nagy B, et al. Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples[J]. Int J Mol Sci, 2019, 20(17):4119. doi: 10.3390/ijms20174119. doi: 10.3390/ijms20174119
[21]	Chan KC, Jiang P, Zheng YW, et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing[J]. Clin Chem, 2013, 59(1):211-224. doi: 10.1373/clinchem.2012.196014. doi: 10.1373/clinchem.2012.196014
[22]	Kim YM, Lee SW, Lee YJ, et al. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma[J]. J Gynecol Oncol, 2019, 30(3):e32. doi: 10.3802/jgo.2019.30.e32. doi: 10.3802/jgo.2019.30.e32
[23]	Du ZH, Bi FF, Wang L, et al. Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer[J]. Mol Genet Genomic Med, 2018, 6(4):638-647. doi: 10.1002/mgg3.414. doi: 10.1002/mgg3.414
[24]	Christie EL, Fereday S, Doig K, et al. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer[J]. J Clin Oncol, 2017, 35(12):1274-1280. doi: 10.1200/JCO.2016.70.4627. doi: 10.1200/JCO.2016.70.4627
[25]	Arend RC, Londoño AI, Montgomery AM, et al. Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma[J]. Mol Cancer Res, 2018, 16(5):813-824. doi: 10.1158/1541-7786.MCR-17-0594. doi: 10.1158/1541-7786.MCR-17-0594
[26]	Jagelkova M, Zelinova K, Laucekova Z, et al. Comparison of Somatic Mutation Profiles Between Formalin-Fixed Paraffin Embedded Tissues and Plasma Cell-Free DNA from Ovarian Cancer Patients Before and After Surgery[J]. Biores Open Access, 2020, 9(1):73-79. doi: 10.1089/biores.2019.0031. doi: 10.1089/biores.2019.0031 pmid: 32219013
[27]	Kamat AA, Bischoff FZ, Dang D, et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma[J]. Cancer Biol Ther, 2006, 5(10):1369-1374. doi: 10.4161/cbt.5.10.3240. doi: 10.4161/cbt.5.10.3240
[28]	Parkinson CA, Gale D, Piskorz AM, et al. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study[J]. PLoS Med, 2016, 13(12):e1002198. doi: 10.1371/journal.pmed.1002198. doi: 10.1371/journal.pmed.1002198
[29]	Noguchi T, Iwahashi N, Sakai K, et al. Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact[J]. Cancers(Basel), 2020, 12(11):3382. doi: 10.3390/cancers12113382. doi: 10.3390/cancers12113382
[30]	Paracchini L, Beltrame L, Grassi T, et al. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer[J]. Clin Cancer Res, 2021, 27(9):2549-2559. doi: 10.1158/1078-0432.CCR-20-3345. doi: 10.1158/1078-0432.CCR-20-3345
[31]	Alves MC, Fonseca F, Yamada A, et al. Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study[J]. Tumour Biol, 2020, 42(5):1010428320919198. doi: 10.1177/1010428320919198. doi: 10.1177/1010428320919198
[32]	Rusan M, Andersen RF, Jakobsen A, et al. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer[J]. Eur J Cancer, 2020, 125:121-129. doi: 10.1016/j.ejca.2019.11.012. doi: 10.1016/j.ejca.2019.11.012
[33]	Vidula N, Rich TA, Sartor O, et al. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors[J]. Clin Cancer Res, 2020, 26(11):2546-2555. doi: 10.1158/1078-0432.CCR-19-2933. doi: 10.1158/1078-0432.CCR-19-2933
[34]	Lin KK, Harrell MI, Oza AM, et al. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma[J]. Cancer Discov, 2019, 9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. doi: 10.1158/2159-8290.CD-18-0715